Stock 600488 TIANJIN TIANYAO PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Tianjin Tianyao Pharmaceuticals Co., Ltd. Share Price

Equities

600488

CNE000001840

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
4.09 CNY +1.49% Intraday chart for Tianjin Tianyao Pharmaceuticals Co., Ltd. +9.36% -16.53%
26/04 Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
25/04 Jinyao Pharma's Unit Gets Approval to Market Compound Ipratropium Bromide Solution MT

Financials

Sales 2022 3.69B 510M 42.46B Sales 2023 3.78B 523M 43.54B Capitalization 5.36B 740M 61.69B
Net income 2022 35M 4.83M 403M Net income 2023 117M 16.16M 1.35B EV / Sales 2022 1.52 x
Net Debt 2022 756M 104M 8.7B Net Debt 2023 233M 32.2M 2.68B EV / Sales 2023 1.48 x
P/E ratio 2022
138 x
P/E ratio 2023
45.8 x
Employees 2,678
Yield 2022
0.23%
Yield 2023
1.78%
Free-Float 42.94%
More Fundamentals * Assessed data

Chart Tianjin Tianyao Pharmaceuticals Co., Ltd.

Dynamic Chart

Latest news about Tianjin Tianyao Pharmaceuticals Co., Ltd.

Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jinyao Pharma's Unit Gets Approval to Market Compound Ipratropium Bromide Solution MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jinyao Pharma Unit's Fluconazole Chloride Passes Regulatory Evaluation MT
Jinyao Pharma Unit's Metoclopramide Hydrochloride Injection Passes Regulatory Evaluation MT
Jinyao Pharma Unit's Clindamycin Phosphate Passes Drug Regulator's Evaluation MT
Jinyao Pharmaceutical's Drugs Chosen for China's Centralized Procurement Bid MT
Jinyao Pharmaceutical Gets Nod to Market Travoprost MT
Tianyao Pharma’s Brain Injury Drug Passes Generic Drug Consistency Test MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jinyao Pharmaceutical Unit's Methylcobalamin Injection Passes Drug Regulator's Evaluation MT
Jinyao Pharmaceutical Gets Nod to Market Two Raw Drug Materials MT
Tianjin Tianyao Pharmaceuticals Co., Ltd.(XSSC:600488) added to S&P Global BMI Index CI
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jinyao Pharmaceutical Unit's Tumor Drug Passes Regulatory Evaluation MT
More news

Quotes and Performance

1 day+1.49%
1 week+9.36%
Current month+2.76%
1 month+2.76%
3 months-6.19%
6 months-19.80%
Current year-16.53%
More quotes

Highs and lows

1 week
3.76
Extreme 3.76
4.09
1 month
3.58
Extreme 3.58
4.09
Current year
3.10
Extreme 3.1
5.09
1 year
3.10
Extreme 3.1
6.26
3 years
3.10
Extreme 3.1
6.26
5 years
3.10
Extreme 3.1
6.26
10 years
3.10
Extreme 3.1
13.29
More quotes

Managers and Directors - Tianjin Tianyao Pharmaceuticals Co., Ltd.

Managers TitleAgeSince
Shu Xiang Li CEO
 Chief Executive Officer 52 10/22/10
Juan Li BRD
 Director/Board Member 44 13/20/13
Yong Yan Chi
51 -
Members of the board TitleAgeSince
Hua Xu CHM
 Chairman 58 18/22/18
Wei Zhao CHM
 Chairman 55 22/23/22
Yong Yan Chi BRD
 Director/Board Member 51 29/19/29
More insiders

ETFs positioned on Tianjin Tianyao Pharmaceuticals Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.04% -
More ETFs positioned on Tianjin Tianyao Pharmaceuticals Co., Ltd.

Quotes

Date Price Change Volume
30/24/30 4.09 +1.49% 10,646,400
29/24/29 4.03 +3.07% 10,140,950
26/24/26 3.91 +0.51% 5,777,201
25/24/25 3.89 +1.30% 6,596,100
24/24/24 3.84 +1.05% 6,121,659

End-of-day quote Shanghai S.E., April 30, 2024

More quotes

Company Profile

Jinyao Pharmaceutical Co Ltd, formerly Tianjin Tianyao Pharmaceuticals Co., Ltd., is a China-based company mainly engaged in the research and development, production and sales of corticosteroids and amino acid APIs and preparations. The Company's main products include dexamethasone series, prednisone series, methylprednisolone series, betamethasone series and more than 40 varieties of corticosteroid raw materials, 23 varieties of amino acid raw materials, and 16 dosage forms such as tablets, injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, and inhalation preparations. The Company mainly operates in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
28/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
TIANJIN TIANYAO PHARMACEUTICALS CO., LTD. Stock Tianjin Tianyao Pharmaceuticals Co., Ltd.
-16.53% 618M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600488 Stock